Abstract
Qiagen has selected Angle’s Parsortix system as its circulating tumor cell (CTC) harvesting technology, and Parsortix will be cross-promoted with Qiagen’s liquid biopsy solution portfolio, through a co-marketing agreement.
Parsortix, launched in 2014, is an epitope-independent CTC solution not dependent on the use of antibodies or membranes. The system is designed to offer easy, automated processing of whole blood in order to harvest all types of CTCs, including mesenchymal CTCs, for analysis. Harvesting is enabled by a step-based reverse flow system.
“The modular combination abilities of this system with Qiagen’s liquid biopsy-based ‘Sample to Insight’ offering—including AdnaTest, our targeted RNAseq and single cell solutions, along with our bioinformatics offering—will allow scientists and clinical researchers to significantly advance their research,” Michael Kazinski, Qiagen’s senior director, molecular preanalytic technologies, said in a statement.
AlexRaths / Getty Images
Parsortix will be marketed in tandem with Qiagen’s liquid biopsy portfolio, consisting of products that offer next-generation sequencing (NGS), polymerase chain reaction (PCR), single-cell analysis products and bioinformatics capabilities.